Evidence map›Paper›PMID 36003795›Full record

ArticleFrontiers in oncology2022

Revealing the intratumoral heterogeneity of non-DS acute megakaryoblastic leukemia in single-cell resolution.

Narun Su, Zifeng Li, Jiapeng Yang, Yang Fu, Xiaohua Zhu, Hui Miao, Yi Yu, Wenjin Jiang, Jun Le, Xiaowen Qian and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Narun SuDepartment of Hematology and Oncology, National Children's Medical Center, Children's Hospital of Fudan University, Shanghai, China.
Zifeng LiDepartment of Hematology and Oncology, National Children's Medical Center, Children's Hospital of Fudan University, Shanghai, China.
Jiapeng YangDepartment of Hematology and Oncology, National Children's Medical Center, Children's Hospital of Fudan University, Shanghai, China.
Yang FuDepartment of Hematology and Oncology, National Children's Medical Center, Children's Hospital of Fudan University, Shanghai, China.
Xiaohua ZhuDepartment of Hematology and Oncology, National Children's Medical Center, Children's Hospital of Fudan University, Shanghai, China.
Hui MiaoDepartment of Hematology and Oncology, National Children's Medical Center, Children's Hospital of Fudan University, Shanghai, China.
Yi YuDepartment of Hematology and Oncology, National Children's Medical Center, Children's Hospital of Fudan University, Shanghai, China.
Wenjin JiangDepartment of Hematology and Oncology, National Children's Medical Center, Children's Hospital of Fudan University, Shanghai, China.
Jun LeDepartment of Hematology and Oncology, National Children's Medical Center, Children's Hospital of Fudan University, Shanghai, China.
Xiaowen QianDepartment of Hematology and Oncology, National Children's Medical Center, Children's Hospital of Fudan University, Shanghai, China.
Hongsheng WangDepartment of Hematology and Oncology, National Children's Medical Center, Children's Hospital of Fudan University, Shanghai, China.
Maoxiang QianNational Children's Medical Center and the Shanghai Key Laboratory of Medical Epigenetics, Institute of Pediatrics, Institutes of Biomedical Sciences, Children's Hospital of Fudan University, Fudan University, Shanghai, China.
Xiaowen ZhaiDepartment of Hematology and Oncology, National Children's Medical Center, Children's Hospital of Fudan University, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pediatric acute megakaryoblastic leukemia (AMKL) is a subtype of acute myeloid leukemia (AML) characterized by abnormal megakaryoblasts, and it is divided into the AMKL patients with Down syndrome (DS-AMKL) and AMKL patients without DS (non-DS-AMKL). Pediatric non-DS-AMKL is a heterogeneous disease with extremely poor outcome. We performed single-cell RNA sequencing (scRNA-seq) of the bone marrow from two

Indexed as

acute megakaryoblastic leukemiaCD81intratumoral heterogeneitynon-DS-AMKLRACK1single cell RNA sequencing

Identifiers

PMID36003795
PMCPMC9394455

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.